# BPC-157

BPC-157 is a synthetic 15-amino-acid peptide. It is based on a sequence found in human gastric juice. It is marketed for healing your tendons, ligaments, and gut. Animal studies hint at pro-angiogenic (blood-vessel-growing) and tissue-repair effects. But the human trial data are very limited, just a few small pilot studies, with no large, well-controlled RCTs. It is not approved by the FDA or EMA. Injectable BPC-157 was placed on the FDA's 503A Category 2 list (significant safety concerns), among interim bulk drug substances. It was removed from Category 2 on 22 April 2026, alongside eleven other peptides whose nominators withdrew. A Pharmacy Compounding Advisory Committee (PCAC) review is scheduled for 23 to 24 July 2026. But that is not an approval. BPC-157 stays unauthorized for any therapeutic use. And it is banned at all times under WADA category S0 (Unapproved Substances).

## Sources

- Sikiric P, Seiwerth S, Grabarevic Z et al.. (1999). The pharmacological properties of the novel peptide BPC 157 (PL-10). Inflammopharmacology. https://doi.org/10.1007/s10787-999-0022-z
- Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. https://doi.org/10.1177/15563316251355551

---

_Canonical: https://longevity-switzerland.com/en/glossary/bpc-157 · Part of Longevity Cities · Updated 2026-06-22_